Lisata Therapeutics expands board to 8, appoints Jeff Farrow as Class III director and audit committee member

LISATA THERAPEUTICS, INC.

Board voted October 13, 2026 to increase size from seven to eight members and appointed Jeffrey Farrow (age 65) to the newly created seat, effective immediately.
Farrow's initial term expires at the 2028 annual meeting; he was also named to the Audit Committee and is independent under Nasdaq rules.
Farrow is currently CFO and Chief Strategy Officer of Tarsus Pharmaceuticals (Nasdaq: TARS), a role held since April 2023.
Prior roles: CFO of Global Blood Therapeutics through its Pfizer acquisition (2016-2022), CFO of ZS Pharma (acquired by AstraZeneca, 2015) and CFO of Hyperion Therapeutics (acquired by Horizon, 2015).
CEO David Mazzo cited Farrow's financial discipline as Lisata advances Phase 2b programs in severe hypertriglyceridemia and acromegaly.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.